Lilian Schwarz1, Michael Bubenheim2, Isabelle Gardin3, Emmanuel Huet4, Ghassan Riachi5, Erick Clavier6, Odile Goria5, Pierre Vera3, Michel Scotté4. 1. Department of Digestive Surgery, Rouen University Hospital-Charles Nicolle, Rouen, France. lilian.schwarz@gmail.com. 2. Department of Biostatistics, Rouen University Hospital, Rouen, France. 3. Department of Nuclear Medicine, Henri Becquerel Center and Rouen University Hospital, Rouen, France. 4. Department of Digestive Surgery, Rouen University Hospital-Charles Nicolle, Rouen, France. 5. Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France. 6. Department of Radiology, Rouen University Hospital, Rouen, France.
Abstract
BACKGROUND AND OBJECTIVES: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence. METHODS: Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available. RESULTS: Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014). CONCLUSIONS: Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.
BACKGROUND AND OBJECTIVES: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131lipiodol on survival and recurrence. METHODS: Between 2004 and 2010, 38 patients were treated with adjuvant I-131lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131lipiodol treatment became available. RESULTS: Recurrence-free survival in the control and in the I-131lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014). CONCLUSIONS: Adjuvant I-131lipiodol improves disease-free survival in patients with HCC.
Authors: W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: H S Yoo; C H Park; J T Lee; K W Kim; C S Yoon; J H Suh; C Y Park; B S Kim; H J Choi; K S Lee Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333